Omics data address key issues in liver transplantation(LT)as the most effective therapeutic means for end-stage liver *** purpose of this study was to review the current application and future direction for omics in *...
详细信息
Omics data address key issues in liver transplantation(LT)as the most effective therapeutic means for end-stage liver *** purpose of this study was to review the current application and future direction for omics in *** reviewed the use of multiomics to elucidate the pathogenesis leading to LT and *** directions with respect to the use of omics in LT are also described based on perspectives of surgeons with experience in *** molecules were identified and summarized based on omics,with a focus on post-transplant liver fibrosis,early allograft dysfunction,tumor recurrence,and graft *** emphasized the importance omics for clinicians who perform LTs and prioritized the directions that should be *** also outlined the ideal workflow for omics in *** step with advances in technology,the quality of omics data can be guaranteed using an improved algorithm at a lower *** should be addressed on the translational value of omics for better therapeutic effects in patients undergoing LT.
Background Alzheimer’s disease(AD)is associated with metabolic abnormalities linked to critical elements of *** recently administered combined metabolic activators(CMA)to the AD rat model and observed that CMA improv...
详细信息
Background Alzheimer’s disease(AD)is associated with metabolic abnormalities linked to critical elements of *** recently administered combined metabolic activators(CMA)to the AD rat model and observed that CMA improves the AD-associated histological parameters in the *** promotes mitochondrial fatty acid uptake from the cytosol,facilitates fatty acid oxidation in the mitochondria,and alleviates oxidative *** Here,we designed a randomised,double-blinded,placebo-controlled phase-II clinical trial and studied the effect of CMA administration on the global metabolism of AD ***-dose CMA included 12.35 g L-serine(61.75%),1 g nicotinamide riboside(5%),2.55 g N-acetyl-L-cysteine(12.75%),and 3.73 g L-carnitine tartrate(18.65%).AD patients received one dose of CMA or placebo daily during the first 28 days and twice daily between day 28 and day *** primary endpoint was the difference in the cognitive function and daily living activity scores between the placebo and the treatment *** secondary aim of this study was to evaluate the safety and tolerability of CMA.A comprehensive plasma metabolome and proteome analysis was also performed to evaluate the efficacy of the CMA in AD *** We showed a significant decrease of AD Assessment Scale-cognitive subscale(ADAS-Cog)score on day 84 vs day 0(P=0.00001,29%improvement)in the CMA ***,there was a significant decline(P=0.0073)in ADAS-Cog scores(improvement of cognitive functions)in the CMA compared to the placebo group in patients with higher ADAS-Cog *** cognitive functions in AD patients were supported by the relevant alterations in the hippocampal volumes and cortical thickness based on imaging ***,the plasma levels of proteins and metabolites associated with NAD+and glutathione metabolism were significantly improved after CMA *** Our results indicate that treatment of AD patients with CMA can lead to enhanced cognit
暂无评论